SARS-CoV-2 - Baricitinib - Therapeutic Candidates

SARS-CoV-2 - Baricitinib - Therapeutic Candidates


Like ruxolitinib, baricitinib (OLUMIANT) is an inhibitor of Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) which are tyrosine kinases involved in JAK signaling pathways. Baricitinib is a reversible and selective inhibitor and is indicated in the treatment of moderate to severe active rheumatoid arthritis for its anti-inflammatory effect. It is a second-line therapy, i.e., used after failure of conventional disease-modifying therapies. It can be used alone or in combination with methotrexate (MTX).
A clinical study on the efficacy and safety of baricitinib for the treatment of Covid-19 has begun. The anti-inflammatory activity of this drug may have a potential beneficial effect in the treatment of Covid-19. The use of baritinicib therapy may limit the cytokine release syndrome associated with Covid-19 and may be useful because it acts against a wide range of cytokines.

Search result : 202 product found

Refine your search :

RUOCE / IVD
  • Unconjugated 61
  • Biochemicals 130
  • Inhibitor/Antagonist/Agonist 72
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
M2039-5mg
 5mg 
orb1901580-5mg
 5mg 
orb1305415-2mg
 2mg 
orb1090030-25mg
 25mg 
orb1227510-250mg
 250mg 
orb1090030-50mg
 50mg 
orb1226853-100mg
 100mg 
orb1305415-5mg
 5mg 
orb1226853-25mg
 25mg 
orb1305415-50mg
 50mg 
orb1901579-50mg
 50mg 
orb1226853-10mg
 10mg 
orb669003-5mg
 5mg 
orb1305415-100mg
 100mg 
orb1226853-5mg
 5mg 
orb1090030-5mg
 5mg 
orb1226853-50mg
 50mg 
orb1901583-10mg
 10mg 
orb1305415-1mg
 1mg